Skip to main content

TYVASO is approved for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve the ability to exercise.

Skip to main content
Hamburger button
Close button

PATIENTS TAKING TYVASO WALKED FARTHER

The 6-minute walk test

PH-ILD can make it difficult for you to walk more than a short distance. The 6-minute walk test (6MWT) can give you a good clue about how much your lung disease could be impacting your ability to stay active. It measures how far you can walk in 6 minutes.

 

 

TYVASO has been shown to help patients with PH-ILD be more active

In a 16-week PH-ILD clinical study, 6MWTs were compared for people who took TYVASO and those who took a placebo (an inhaled solution without medicine in it).

6mwt results from 16 week PH-ILD clinical study6mwt results from 16 week PH-ILD clinical study
In addition to being able to walk farther, patients taking TYVASO also had less strain on their heart.